Hao Tang

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests

Hao Tang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

Helen Gogas
Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece
18 shared publications
Paolo Antonio Ascierto
Universita Degli Studi Di Napoli Federico II, Naples, Italy
18 shared publications
Sonia Dolfi
Bristol Myers Squibb, Princeton, New Jersey, USA
18 shared publications
Antonella Mazzei
Bristol Myers Squibb, Princeton, New Jersey
12 shared publications
Charlie Garnett-Benson
Bristol Myers Squibb, Princeton, New Jersey, USA
12 shared publications
Dirk Schadendorf
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
12 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
by James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, et al.
DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
by James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, et al.
DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Changes in immune cell populations in the NIVO + RELA arm from baseline to week 4.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Changes in immune cell populations in the NIVO + RELA arm from baseline to week 4.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Representativeness of study participants.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Representativeness of study participants.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Additional associations of on-treatment changes in CD8+ CM and CD4+ EM cell populations with best overall response.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Additional associations of on-treatment changes in CD8+ CM and CD4+ EM cell populations with best overall response.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Association between MHC-I or MHC-II and PFS or ORR in patients treated with NIVO + RELA or NIVO.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Association between MHC-I or MHC-II and PFS or ORR in patients treated with NIVO + RELA or NIVO.
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Characterization of gene signatures in tumor samples associated with treatment arm, NIVO + RELA (A) versus NIVO (B); and type of response, CR/PR (C) versus PD (D).
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
Characterization of gene signatures in tumor samples associated with treatment arm, NIVO + RELA (A) versus NIVO (B); and type of response, CR/PR (C) versus PD (D).
Open Access
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
CD8 characterization in the TME.
Website
Google Scholar
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
by Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, et al.
CD8 characterization in the TME.

Show all